Kalaris Therapeutics, Inc. (KLRS)

NGM – Real Time Price. Currency in USD

3.99

+0.02 (0.50%)

Market open: Aug 12, 2026, 1:33 PM EDT

4.04

+0.07 (1.76%)

Previous after-hours: Aug 11, 2026, 7:40 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Revenue

Gross Profit

Operating Income

Net Income

Income Statement
Balance Sheet
Cash Flow

Income Statement (Annual)

Financials in millions USD. Fiscal year is January – December.

Name

2025

2024

2023

2022

Total Revenue

Cost of goods sold

-13K

-398K

-3M

Gross Profit

-13K

-398K

-3M

Operating expenses (excl. COGS)

-46M

-52M

-181M

-169M

Operating Income

-46M

-52M

-181M

-171M

Non-operating income, total

-17M

-9M

Pretax income

-43M

-69M

-191M

-169M

Equity in earnings

Taxes

126K

265K

Non-controlling/minority interest

After tax other income/expense

Net income before discontinued operations

-43M

-69M

-190M

-169M

Discontinued operations

Net income

-43M

-69M

-190M

-169M

Dilution adjustment

Preferred dividends

Kalaris Therapeutics, Inc. (KLRS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Kalaris Therapeutics, Inc. (KLRS)

Income Statement (Annual)

Income Statement (Annual)

Search stocks

Kalaris Therapeutics, Inc. (KLRS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Kalaris Therapeutics, Inc. (KLRS)

Income Statement (Annual)

Income Statement (Annual)